{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:39Z","timestamp":1746417759165,"version":"3.40.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"crossref","award":["200-2001-00133, 200-2006-18797, 200-2011-41872, 200-2015-63931"],"award-info":[{"award-number":["200-2001-00133, 200-2006-18797, 200-2011-41872, 200-2015-63931"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The aim of this study was to identify viral exposure (VE) measures and their relationship to mortality risk among persons with HIV.<\/jats:p>\n            <jats:p>Prospective multicenter observational study to compare VE formulae.<\/jats:p>\n            <jats:p>Eligible participants initiated first combination antiretroviral therapy (cART) between March 1, 1995 and June 30, 2015. We included 1645 participants followed for \u22656\u200amonths after starting first cART, with cART prescribed \u226575% of time, who underwent \u22652 plasma viral load (VL) and \u22651 CD4+ T-lymphocyte cell (CD4) measurement during observation. We evaluated all-cause mortality from 6\u200amonths after cART initiation until June 30, 2016. VE was quantified using 2 time-updated variables: viremia copy-years and percent of person-years (%PY) spent &gt;200 or 50\u200acopies\/mL. Cox models were fit to estimate associations between VE and mortality.<\/jats:p>\n            <jats:p>Participants contributed 10,453 person years [py], with median 14 VLs per patient. Median %PY &gt;200 or &gt;50 were 10% (interquartile range: 1%\u201347%) and 26% (interquartile range: 6%\u201372%), respectively. There were 115 deaths, for an overall mortality rate of 1.19 per 100 person years. In univariate models, each measure of VE was significantly associated with mortality risk, as were older age, public insurance, injection drug use HIV risk history, and lower pre-cART CD4. Based on model fit, most recent viral load and %PY &gt;200\u200acopies\/mL provided the best combination of VE factors to predict mortality, although all VE combinations evaluated performed well.<\/jats:p>\n            <jats:p>The combination of most recent VL and %PY &gt;200\u200acopies\/mL best predicted mortality, although all evaluated VE measures performed well.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026285","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:26:38Z","timestamp":1624454798000},"page":"e26285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["HIV viral exposure and mortality in a multicenter ambulatory HIV adult cohort, United States, 1995\u20132016"],"prefix":"10.1097","volume":"100","author":[{"given":"Frank J.","family":"Palella","sequence":"first","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-4485","authenticated-orcid":false,"given":"Carl","family":"Armon","sequence":"additional","affiliation":[{"name":"Cerner Corporation, Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Cole","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Hart","sequence":"additional","affiliation":[{"name":"Cerner Corporation, Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Tedaldi","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine at Temple University, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Novak","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Battalora","sequence":"additional","affiliation":[{"name":"Cerner Corporation, Kansas City, MO"},{"name":"Colorado School of Mines, Golden, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Purinton","sequence":"additional","affiliation":[{"name":"Cerner Corporation, Kansas City, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Buchacz","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1089\/088922200414965","article-title":"Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a, meta-analysis. HIV Surrogate Marker Collaborative Group","volume":"16","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort, studies","volume":"372","year":"2008","journal-title":"Lancet (London, England)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(03)14229-8","article-title":"Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies","volume":"362","author":"Chene","year":"2003","journal-title":"Lancet (London, England)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/513823","article-title":"Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy","volume":"177","author":"Marschner","year":"1998","journal-title":"J Infect Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00002030-199905070-00008","article-title":"The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs","volume":"13","author":"Murray","year":"1999","journal-title":"AIDS (London, England)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.0800050105","article-title":"Low-level viremia persists for at least 7\u200ayears in patients on suppressive antiretroviral therapy","volume":"105","author":"Palmer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/cid\/ciu722","article-title":"High rates of retention and viral suppression in the US HIV safety net system: HIV care continuum in the Ryan White HIV\/AIDS Program, 2011","volume":"60","author":"Doshi","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet (London, England)"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/QAI.0b013e31827df36c","article-title":"Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis","volume":"62","author":"Justice","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/QAI.0000000000000289","article-title":"Cumulative HIV viremia and non-AIDS-defining malignancies among a sample of HIV-infected male veterans","volume":"67","author":"Kowalkowski","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1097\/QAD.0000000000001144","article-title":"Associations between HIV-RNA-based indicators and virological and clinical outcomes","volume":"30","author":"Laut","year":"2016","journal-title":"AIDS (London, England)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet (London, England)"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/0003-4819-157-5-201209040-00005","article-title":"U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008","volume":"157","author":"Althoff","year":"2012","journal-title":"Ann Intern Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12\u200ayears of observation","volume":"57","author":"Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/00002030-200210180-00008","article-title":"Prevalence and clinical correlates of HIV viremia (\u2018blips\u2019) in patients with previous suppression below the limits of quantification","volume":"16","author":"Sklar","year":"2002","journal-title":"AIDS (London, England)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAI.0000000000001036","article-title":"Single viral load measurements overestimate stable viral suppression among HIV patients in care: clinical and public health implications","volume":"73","author":"Marks","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/QAI.0000000000000416","article-title":"Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment","volume":"68","author":"Chirouze","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/aje\/kwp347","article-title":"Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden","volume":"171","author":"Cole","year":"2010","journal-title":"Am J Epidemiol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/QAI.0000000000000125","article-title":"Determinants of viremia copy-years in people with HIV\/AIDS after initiation of antiretroviral therapy","volume":"66","author":"Wright","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/QAD.0000000000000640","article-title":"Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care","volume":"29","author":"Marks","year":"2015","journal-title":"AIDS (London, England)"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/cir526","article-title":"Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy","volume":"53","author":"Mugavero","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/aje\/kwv303","article-title":"Reevaluating cumulative HIV-1 viral load as a prognostic predictor: predicting opportunistic infection incidence and mortality in a Ugandan cohort","volume":"184","author":"Sempa","year":"2016","journal-title":"Am J Epidemiol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1097\/QAD.0000000000001986","article-title":"Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?","volume":"32","author":"Wang","year":"2018","journal-title":"AIDS (London, England)"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1093\/jac\/dkw307","article-title":"Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study","volume":"71","author":"Quiros-Roldan","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciw564","article-title":"Baseline, time-updated, and cumulative HIV care metrics for predicting acute myocardial infarction and all-cause mortality","volume":"63","author":"Salinas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/599313","article-title":"Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma","volume":"200","author":"Zoufaly","year":"2009","journal-title":"J Infect Dis"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/cid\/ciw418","article-title":"Durable viral suppression and transmission risk potential among persons with diagnosed HIV infection: United States, 2012-2013","volume":"63","author":"Crepaz","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R31-20250504","first-page":"2033","article-title":"Time spent with HIV viral load above 1500\u200acopies\/ml among patients in HIV care","volume":"32","author":"Mendoza","year":"2018","journal-title":"2000-2014 AIDS (London, England)"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1047-2797(99)00005-8","article-title":"Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS)","volume":"9","author":"Moorman","year":"1999","journal-title":"Ann Epidemiol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/376992","article-title":"Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression","volume":"37","author":"Holmberg","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-151-2-200907210-00003","article-title":"The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study","volume":"151","author":"Palella","year":"2009","journal-title":"Ann Intern Med"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/QAD.0b013e32834b3537","article-title":"Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment","volume":"25","author":"Palella","year":"2011","journal-title":"AIDS (London, England)"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","article-title":"Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata","volume":"138","author":"Palella","year":"2003","journal-title":"Ann Intern Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:04:08Z","timestamp":1746338648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":37,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026285","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2020-08-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}